Risk Factors of Metabolic Syndrome among Clinic Patients in Gaza - Palestine

Amal Jamee^1, , Yehia Abed² and Hassan Abutawila³

¹AL Shifa Hospital, Cardiology department, Gaza, Palestine

²Al Quds University, Faculty of Public Health, Gaza, Palestine

³Private clinic, Former Director General AL Shifa Hospital Gaza, Palestine

Cite this paper:
Amal Jamee, Yehia Abed and Hassan Abutawila. Risk Factors of Metabolic Syndrome among Clinic Patients in Gaza - Palestine. American Journal of Cardiovascular Disease Research. 2013; 1(1):20-24. doi: 10.12691/ajcdr-1-1-5

Abstract

Metabolic syndrome is a term, which refers to a combination of medical disorders that are associated with a higher risk for cardiovascular disease and diabetes. The syndrome is more common in female than males. This study was conducted to estimate the prevalence of the metabolic syndrome among patients with cardiovascular diseases in Gaza and to examine the association between traditional risk factors for the non-communicable diseases and each of the component of the metabolic syndrome. We used the Adult Treatment Protocol III National cholesterol Education Programme of America (ATPIII) indicators for diagnosis and determination of metabolic syndrome. The syndrome was met if an individual had three or more criteria: waist circumference >102cm in men and >88cm in women, fasting plasma glucose ≥110mg/dl, Blood pressure ≥130/85mmhg, serum Triglycerides ≥150mg/dl and serum HDL cholesterol <40mg/dl in male and <50mg/dl in female. Statistical analysis was performed using SPSS version 20. The prevalence of metabolic syndrome was 59.5%, without difference between male and female. The main risk factors for metabolic syndrome were high blood pressure (78.8% for systolic and 73.8% for diastolic Blood Pressure), large waist circumference (67.9%), high Triglycerides (78.6%), and high fasting blood sugar (86.4%). HDL cholesterol was protective but not statistically significant. The risk factors of metabolic syndrome in both sexes in descending order were as follows, high fasting blood sugar, large waist circumference, high Triglycerides, high Blood Pressure, and low HDL cholesterol. We conclude that high level of prevalence of metabolic syndrome in our study population indicates the need for an active health programme to reduce the factors influencing the prevalence. Therefore, preventive interventions must be taken seriously.

Keywords:
metabolic syndrome prevalence and risk factors cardiovascular disease Gaza Palestine

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Eva Kassi, Panagiota Pervanidou, Gregory Kaltsas and George Chrousos “Metabolic syndrome: definitions and controversies,” BMC Medicine, 9. 48. 2011.
[2]	Jaber LA, Brown MB, Hamm ad A, Zhu Q, Herman WH, “The prevalence of the metabolic syndrome among Arab Americans,” Diabetes Care, 27 (1). 234-238. 2004.
[3]	Reaven GM, “Role of insulin resistance inhuman disease” Banting lecture Diabetes, 37. 1595-1607.1988.
[4]	DeFronzo RA, Ferrannini E, “Insulin resistance, a multifaceted Syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease,” Diabetes Care, 14. 173-194. 1991.
[5]	Kaplan NM, “The deadly quartet, Upper-body obesity, glucose intolerance hypertriglyceridemia, and hypertension,” Arch Intern Med, 149. 1514-1520. 1989.
[6]	Aguilar-Salinas CA, Rojas R, Gomez-Perez FJ, Mehta R, Franco A, Olaiz G, et al, “The metabolic syndrome: a concept hard to define,” Arch Med Res, 36 (3). 223-231. 2005.
[7]	Abu Sham’s RA, Dawazah AK, Kufri FH, Yassin IH, Torok NI, “Metabolic syndrome and cardiovascular risk factors among Palestinian of east Jerusalem,” East Mediterr Health J, 15. 1464-1473. 2009.
[8]	Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al, “American College of Endocrinology position statement on the insulin resistance syndrome,” Endocr Pract, 9. 237-252. 2003.
[9]	Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group, “The metabolic syndrome a new worldwide definition,” Lancet, 366. 1059-1062. 2005.
[10]	Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al, “Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/ NationalHeart,Lung, and Blood Institute Scientific Statement,” Circulation,112. 2735-2752. 2005.
[11]	Balkaua B, Valensic P, Eschwègea E, Slam G, “A review of the metabolic syndrome,” Diabetes Metab, 33. 405-413. 2007.
[12]	Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, et al, “The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study,” Diabetes Metab, 29 (5).526-532. 2003.
[13]	Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V, “ Metabolic syndrome in urban Asian Indian adults, a population study using modified ATP IIIcriteria,” Diabetes Res Clin Pract, 60 (3).199-204. 2003.
[14]	Giulia D’Agostini, Mariantonietta Cicoira, Corrado Vassanelli, “Heart Failure in Women: A Disease with Peculiar Path physiological Mechanisms and Clinical Presentation,” American Journal of Cardiovascular Disease Research, 1(1). 1-6.2013.
[15]	Isomaa B, Almgren P, Tuomi T, et al, “Cardiovascular morbidity and mortality associated with the metabolic syndrome,” Diabetes Care, 24. 683-689. 2001.
[16]	Lakka HM, Laaksonen DE, Lakka TA, et al, “The metabolic syndrome and total cardiovascular disease mortality in middle aged men,” JAMA, 288. 2709-2716. 2002.
[17]	Robert H Eckel, Scott M Grundy, Paul Z, “The metabolic syndrome,” Lancet, 365. 1415-1428.2005.
[18]	Stern M, Williams K, Gonzalez, Villalpando C et al, “Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and or cardiovascular disease?” Diabetes Care, 27(11. 2676-81. 2004.
[19]	Deepa M, Farooq S, Datta M, Deepa R, Mohan V, “Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34), ” Diabetes Metab Res Rev, 23 (2). 127-134. 2007.
[20]	Azizi F, Salehi P, Etemadi A, Zahedi-Asl S, “Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study” Diabetes Res Clin Pract, 61(1). 29-37. 2003.
[21]	Dunstan DW, Zimmet PZ,Welborn TA et al, “The rising prevalence of diabetes and impaired glucose tolerance. The Australian Diabetes, Obesity and Lifestyle Study,”Diabetes Care, 25. 829-834. 2002.
[22]	Hamdy A S, Seham A, Nader N, and Iman ES, “Metabolic syndrome in the Middle East,”Indian J Endocrinol Metab olisme,16(1). 2012.
[23]	Khader Y, Bateiha A, El-Khateeb M, Al- Shaikh A, Ajlouni K, “ High prevalence of the metabolic syndrome among Northern Jordanians,” J Diabetes Complications, 21 (4).214-219.2007.
[24]	Kozan O,Oguz A, Abaci A, Erol C ,Ongen Z, Temizhan A et all, “Prevalence of the metabolic syndrome among Turkish adults,” EUR journal Clin N utr, 61. 548-553. 2007.
[25]	Bouguerra R, Alberi H, Smida H ,Salem LB, Rayana CB, et al, “WC cut off points for identification of abdominal obesity among the Tunisian adult population,” Diabetes Obese Meta, 9.859-868.2007.
[26]	Suhad M. Bahijri, Rajaa M. Al Raddadi, “The Importance of Local Criteria in the Diagnosis of Metabolic Syndrome in Saudi Arabia,” Ther Adv in Endo and Metab 4 (2).51-59.2013.
[27]	Eytan C, Han K, Abigail, Elad G and Moshe G, “Hyperuricemia and Metabolic Syndrome: Lessons from a Large Cohort from Israel,” IMAJ, 14. 2012.
[28]	Ford ES, Giles WH, Dietz WH, “Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey,” JAMA, 287. 356-359. 2002.
[29]	Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB, “The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994,” Arch Intern Med, 163.427-436. 2003.
[30]	Grundy SM, Cleeman JI, Daniels SR, et al, “Diagnosis and management of the metabolic syndrome: An American Heart Association/Nation Heart, Lung, and Blood Institute scientific statement,”.Curr Opin Cardiol, 21.1-6.2006.
[31]	Ervin RB, “Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006,” Natl Health Stat Report, 131-7. 2009.
[32]	G. Mancia, G. Parati, C. Borghi et al, “Hypertension prevalence, Awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study,” Journal of Hypertension, 24 (5) .837-843.2006.
[33]	Athyros VG, Bouloukos VI, Pehlivanidis AN, Papageorgiou AA, Dionysopoulou SG, Symeonidis AN, et al, “The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study,” Diabetes Obese Metab, 7. 397-405. 2005.
[34]	Gami AS, Witt BJ, Howard DE, et al, “Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies,” J Am Coll Cardiol, 49(4). 403-414.2007.